JG
VIGL

Joel Greenblatt’s Vigil Neuroscience VIGL Stock Holding History

Joel Greenblatt’s Portfolio VIGL Stock Details VIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-5,933
Closed -$207K – 1525
2024
Q3 		$207K Buy
+5,933
New +$22K ﹤0.01% 1330

Other funds holding VIGL

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $308M AUM 120.89% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Joel Greenblatt's VIGL Position: Q4 2024 in Review

Joel Greenblatt sold out of Vigil Neuroscience (VIGL) in Q4 2024, closing a stake of 5,933 shares — an estimated $207K sold.

Joel Greenblatt first reported a position in VIGL in Q3 2024 and held it in 1 quarter. The position peaked at $207K in Q3 2024. 51 funds tracked by Wall St. Rank hold VIGL as of Q4 2024.

  • Joel Greenblatt reported no remaining Vigil Neuroscience position as of Q4 2024 after selling out during the quarter.
  • Joel Greenblatt sold 5,933 Vigil Neuroscience shares in Q4 2024, an estimated $207K.
  • Joel Greenblatt first reported a position in Vigil Neuroscience in Q3 2024 and held it in 1 quarter.
  • Joel Greenblatt's Vigil Neuroscience position peaked at $207K in Q3 2024.
  • 51 funds tracked by Wall St. Rank held Vigil Neuroscience as of Q4 2024.

Based on Gotham Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.